Gene therapy was selected as one of the top ten medical innovations in 2021 (selected by the Cleveland Clinic in the United States). Cell and gene therapy has changed the way humans treat genetic diseases and intractable diseases, and is leveraging the entire pharmaceutical ecosystem. With strong policy support, China's CGT development is in the leading position in the world. A large number of excellent research results are entering the key stage of clinical trials. According to the statistics of ARM (Alliance for Regenerative Medicine), more than 1,000 clinical trials from 2017 to 2019 have been carried out or are in. In carried out, the Chinese government awarded thousands of related patents, ranking second in the world, and a total of 45 local companies and four joint ventures in the market led the industry to flourish.
While the cell and gene therapy industry is "turbulent", it is more urgent to deal with the challenges and difficulties it faces. The layout of cell therapy industrialization and commercialization modules, the capture of viral vectors, the implementation of a comprehensive application program for gene therapy products, the development of a new generation of oncolytic viruses, and the research on the clinical transformation of biological drugs under the epidemic environment, etc. are eagerly concerned by many industry professionals and need to be answered urgently.
The T-Bio Asia Biomedical Industry Innovation Summit hosted by Taas Labs was successfully held from September 3rd to 4th this year. The event was supported by Shanghai Biomedical Industry Association, Shanghai Institute of Materia Medica, Chinese Academy of Sciences and other authoritative organizations and has achieved complete success. On this basis, the T-Bio series of summits - CGT Asia2021 Asia Cell and Gene Therapy Innovation Summit will be held in Shanghai from March 19th to 20th, 2021. The event is divided into two days. There will be 30+ domestic and foreign industry leaders sharing their experience, insights and application cases. The content will focus on the market prospect and development trend of TCR-T therapy, a new idea for solid tumor treatment, technological innovation in manufacturing cell therapy products, application of stem cell therapy in neurodegenerative diseases, and many other industry hot categories and forward-looking topics. More than 400 domestic and foreign experts, scholars, and business leaders will gather here to focus on creating a gluttonous feast in the field of cell and gene therapy.
Highlights of some topics:
— Cell therapy industrialization and commercialization module layout strategy
— An overview of the new generation of oncolytic viruses combined with immune checkpoint inhibitors
— All-round application program for gene therapy products at home and abroad
—Clinical transformation and biological target verification of cell and gene therapy drugs
—TCR-T therapy market prospect and development trend
—Research progress of stem cell therapy in neurodegenerative diseases
—Research progress of mRNA tumor therapeutic vaccines
— Viral vector process optimization scheme
—Key points for the preparation of nanobodies and bispecific antibodies
— How to grasp the opportunities for the industrialization of cell therapy products?
—Discussion on trends in genomics and personalized medicine, etc.
Part of the participating pharmaceutical companies in the past:
Arnold, Amgen, CStone, BeiGene, Boan Bio, Biogen, CSPC, Dongyao Pharmaceutical, Henlius, Simcere, HighCom, Innovent, Sinopharm, Sinopharm Banner, Hangzhou Jiuyuan Genetic Engineering, Harbor Bio, Huya Bio, China Resources Bio, China Resources Double Crane, Jimin Credible, Jiahe Bio, Tigermed, I-Mab, Yunnan Watson Bio, Jiangsu Hengrui Medicine, Jiangsu Kangyuan Pharmaceutical, Jiangsu Quanxin Bio, Green Ye Pharmaceutical Group, Merck, MSD, Nanjing Chia Tai Tianqing Pharmaceutical, Nuocheng Jianhua, Novartis, Sunshine Guojian Pharmaceutical, Bangyao Biological, Shanghai Fosun Pharmaceutical, Yangzijiang Pharmaceutical, Shanghai Hongbo Zhiyuan Pharmaceutical, Junshi Biological, Qilu Pharmaceutical, Shanghai Renhui Biopharmaceutical, Yangshengtang Group, Shanghai Yingpai Pharmaceutical, Shanghai Zesheng Pharmaceutical, Shanghai Zhongbangsirui Biopharmaceutical, Suzhou Dingfu Target, Zhixiang Pharmaceutical, etc.
Guests will be from:
Biopharmaceutical companies, preclinical R&D, clinical R&D, vaccine/antibody companies, scientific research institutes, biotechnology companies, laboratory equipment suppliers, contract service providers (CRO, CMO, CDMO), drug testing, preparation machinery, production solution providers (upstream, downstream), life science and analytical equipment, diagnostic and testing equipment, pharmaceutical engineering, new drug R&D companies, external licensing, protein drug companies, analytical services, import and export companies, HVAC facilities, clean room equipment suppliers, government representatives/trade agencies, legal and compliance companies, drug delivery system manufacturers, third-party logistics Providers, automation/robots, cold chain packaging companies, packaging machinery, packaging material production enterprises, industrial parks, laboratory services, laboratory/biochemical/analytical instruments, fine chemical production enterprises, environmental protection, intermediate production enterprises, regulatory services, supply chain consulting companies, etc.
Speeches, Sponsorships, Exhibitions and Media Cooperation
Ms. Zhao
Mobile phone: 13341683667 (same as WeChat)
Email: [email protected]
Speeches, Sponsorships, Exhibitions and Media Cooperation
Ms Xu
Mobile phone: 13601679417 (same as WeChat)
Email: [email protected]